InvestSMART

Alterity Therapeutics Limited (ASX:ATH)

ALERT: Price-sensitive ASX Announcement for ATH
Current share price for ATH : $0.645 0.634 (5,763.64%)+
Announcement
Release
31 Oct 2025 9:30AM
Price at Release
$0.011
Full Release
download
Summary
Alterity Therapeutics Limited, an Australian biotechnology company, reported its quarterly cash flow and activities as of 30 September 2025. The company experienced a net cash outflow of A$5.34 million from operating activities, mainly due to expenditures in research and development, staff costs, and administration. It successfully raised A$20 million through equity financing to support its ongoing programs, bringing its cash and cash equivalents to A$54.563 million at the end of the quarter. With no cash flows from investing activities, the company maintained an estimated 10.2 quarters of funding availability. No dividends were paid during this period.
Key Points
  • Alterity Therapeutics Limited reported a net cash outflow from operating activities of A$5.34 million for the quarter.
  • The company raised A$20 million in gross proceeds from a strategic placement to advance its programs.
  • As of 30 September 2025, Alterity had cash and cash equivalents totaling A$54.563 million.
  • Alterity did not have any cash flows from investing activities during the quarter.
  • The estimated quarters of funding available is 10.2 based on current cash flows.
  • The primary use of funds was for research and development, staff costs, and administration.
  • Proceeds from financing activities primarily came from the issue of equity securities.
  • No dividends were paid or proposed by the company during the period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.